81 related articles for article (PubMed ID: 2111135)
1. Mutation rates to 4-quinolone resistance.
Smith JT
Arzneimittelforschung; 1990 Jan; 40(1):65-8. PubMed ID: 2111135
[TBL] [Abstract][Full Text] [Related]
2. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin.
Gilbert DN; Kohlhepp SJ; Slama KA; Grunkemeier G; Lewis G; Dworkin RJ; Slaughter SE; Leggett JE
Antimicrob Agents Chemother; 2001 Mar; 45(3):883-92. PubMed ID: 11181375
[TBL] [Abstract][Full Text] [Related]
3. Influence of temperature on mutational resistance to 4-quinolones.
Parte AC; Smith JT
Arzneimittelforschung; 1996 Apr; 46(4):429-32. PubMed ID: 8740093
[TBL] [Abstract][Full Text] [Related]
4. The selection of resistance to and the mutagenicity of different fluoroquinolones in Staphylococcus aureus and Streptococcus pneumoniae.
Sierra JM; Cabeza JG; Ruiz Chaler M; Montero T; Hernandez J; Mensa J; Llagostera M; Vila J
Clin Microbiol Infect; 2005 Sep; 11(9):750-8. PubMed ID: 16104991
[TBL] [Abstract][Full Text] [Related]
5. Activity of 4-quinolones against Pseudomonas aeruginosa.
Morissey I; Smith JT
Arzneimittelforschung; 1994 Oct; 44(10):1157-61. PubMed ID: 7818593
[TBL] [Abstract][Full Text] [Related]
6. In vitro activity of levofloxacin against coagulase-positive and -negative staphylococci.
Cafiso V; Messina C; Santagati M; Campanile F; Bonfiglio G; Stefani S
Drugs Exp Clin Res; 2001; 27(3):107-11. PubMed ID: 11447768
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of tigecycline against quinolone-resistant Streptococcus pneumoniae, methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci.
Garrison MW; Nuemiller JJ
Int J Antimicrob Agents; 2007 Feb; 29(2):191-6. PubMed ID: 17174074
[TBL] [Abstract][Full Text] [Related]
8. Comparative evaluation of recently developed quinolone compounds--with a note on the frequency of resistant mutants.
Cullmann W; Stieglitz M; Baars B; Opferkuch W
Chemotherapy; 1985; 31(1):19-28. PubMed ID: 3156025
[TBL] [Abstract][Full Text] [Related]
9. Mutant prevention concentration for ciprofloxacin and levofloxacin with Pseudomonas aeruginosa.
Hansen GT; Zhao X; Drlica K; Blondeau JM
Int J Antimicrob Agents; 2006 Feb; 27(2):120-4. PubMed ID: 16426820
[TBL] [Abstract][Full Text] [Related]
10. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration data.
Kowalski RP; Yates KA; Romanowski EG; Karenchak LM; Mah FS; Gordon YJ
Ophthalmology; 2005 Nov; 112(11):1987. PubMed ID: 16183128
[TBL] [Abstract][Full Text] [Related]
11. [Survey on drug resistance to ciprofloxacin in common pathogenic bacteria].
Zhang YL; Geng SN; Lai FC; Wang NP
Di Yi Jun Yi Da Xue Xue Bao; 2002 Apr; 22(4):378-9. PubMed ID: 12390755
[TBL] [Abstract][Full Text] [Related]
12. In vitro studies with five quinolones: evidence for changes in relative potency as quinolone resistance rises.
Thomson KS; Sanders CC; Hayden ME
Antimicrob Agents Chemother; 1991 Nov; 35(11):2329-34. PubMed ID: 1804005
[TBL] [Abstract][Full Text] [Related]
13. Development of resistance to nalidixic acid and the fluoroquinolones after the introduction of norfloxacin and ofloxacin.
Kresken M; Wiedemann B
Antimicrob Agents Chemother; 1988 Aug; 32(8):1285-8. PubMed ID: 3142353
[TBL] [Abstract][Full Text] [Related]
14. Antibacterial activity of a 1,8-naphthyridine quinolone, PD 131628.
Lewin CS
J Med Microbiol; 1992 May; 36(5):353-7. PubMed ID: 1316970
[TBL] [Abstract][Full Text] [Related]
15. Factors influencing fluoroquinolone resistance.
Sahm DF; Thornsberry C; Jones ME; Karlowsky JA
Emerg Infect Dis; 2003 Dec; 9(12):1651-4. PubMed ID: 14725310
[No Abstract] [Full Text] [Related]
16. The selection and frequency of streptococci with decreased susceptibility to ofloxacin compared with other quinolones.
Piddock LJ; Wise R
J Antimicrob Chemother; 1988 Sep; 22 Suppl C():45-51. PubMed ID: 3182461
[TBL] [Abstract][Full Text] [Related]
17. Ofloxacin-loaded liposomes: in vitro activity and drug accumulation in bacteria.
Furneri PM; Fresta M; Puglisi G; Tempera G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2458-64. PubMed ID: 10952595
[TBL] [Abstract][Full Text] [Related]
18. Analysis of antibiotic susceptibilities of skin wound flora in hospitalized dermatology patients. The crisis of antibiotic resistance has come to the surface.
Colsky AS; Kirsner RS; Kerdel FA
Arch Dermatol; 1998 Aug; 134(8):1006-9. PubMed ID: 9722732
[TBL] [Abstract][Full Text] [Related]
19. [Antimicrobial activity of ofloxacin against recent clinical isolates from otitis media and otitis externa].
Matsumoto Y; Suzuki Y; Ishii Y; Ishihara R; Nakazawa A; Nakane Y; Nishinari C; Deguchi K
Jpn J Antibiot; 1998 Sep; 51(9):561-75. PubMed ID: 9846283
[TBL] [Abstract][Full Text] [Related]
20. Ofloxacin, a bactericidal antibacterial.
Smith JT
Chemotherapy; 1991; 37 Suppl 1():2-13. PubMed ID: 1646700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
